Gabexate Mesylate for Injection
Function and Efficacy
Gabexate is a non-peptide protease inhibitor that can inhibit the activity of proteases such as trypsin, kallikrein, plasmin, and thrombin, thereby preventing the pathological and physiological changes caused by these enzymes. In animal experimental acute pancreatitis, it can inhibit activated trypsin and reduce pancreatic damage. At the same time, the increase in serum amylase, lipase activity, and urea nitrogen is also significantly improved.
Ingredients
Gabexate mesylate
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Gabexate mesylateIngredients |
Gabexate is a non-peptide protease inhibitor that can inhibit the activity of proteases such as trypsin, kallikrein, plasmin, and thrombin, thereby preventing the pathological and physiological changes caused by these enzymes. In animal experimental acute pancreatitis, it can inhibit activated trypsin and reduce pancreatic damage. At the same time, the increase in serum amylase, lipase activity, and urea nitrogen is also significantly improved. More |
56974-61-9 | 10 |
Appearance
This product is white or off-white loose mass or powder.
Indication
It is used for the treatment of acute mild (edema type) pancreatitis, and can also be used as an auxiliary treatment for acute hemorrhagic necrotic pancreatitis.
Usage and Dosage
This drug is only for intravenous drip, 100 mg each time, 300 mg daily for the first 3 days of treatment, and 100 mg/day after the symptoms are relieved. The course of treatment is 6-10 days. First, inject 5 ml of injection water into the bottle containing the lyophilized powder of gabexate, and then transfer it into 500 ml of 5% glucose solution or Ringer's solution after it is dissolved for intravenous drip. The drip speed should not be too fast, and should be controlled within 1 mg/kg/hour, and should not exceed 2.5 mg/kg/hour.
Adverse Reactions
In a few cases, local pain in the injected blood vessel, skin redness and other irritation symptoms and mild superficial phlebitis may occur after instillation of this drug. Occasionally, there may be rashes, facial flushing and allergic symptoms. In very rare cases, anaphylactic shock phenomena such as chest tightness, difficulty breathing and drop in blood pressure may occur.
Precautions
It is contraindicated for patients with a history of allergic reactions to multiple drugs.
Special Population Medication
Precautions for children: Children are prohibited from using this product. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.
Drug Interactions
Not yet clear
Storage
Sealed and stored in a cool dark place.
Packaging Specification
0.1 g
Validity Period
48 months